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Abstract: The importance of the nociceptive nervous system for maintaining tissue homeostasis
has been known for some time, and it has also been suggested that organogenesis and tissue
repair are under neuronal control. Changes in peripheral joint innervation are supposed to be
partly responsible for degenerative alterations in joint tissues which contribute to development of
osteoarthritis. Various resident cell types of the musculoskeletal system express receptors for sensory
and sympathetic neurotransmitters, allowing response to peripheral neuronal stimuli. Among them
are mesenchymal stem cells, synovial fibroblasts, bone cells and chondrocytes of different origin,
which express distinct subtypes of adrenoceptors (AR), receptors for vasoactive intestinal peptide
(VIP), substance P (SP) and calcitonin gene-related peptide (CGRP). Some of these cell types synthesize
and secrete neuropeptides such as SP, and they are positive for tyrosine-hydroxylase (TH), the rate
limiting enzyme for biosynthesis of catecholamines. Sensory and sympathetic neurotransmitters are
involved in the pathology of inflammatory diseases such as rheumatoid arthritis (RA) which manifests
mainly in the joints. In addition, they seem to play a role in pathogenesis of priori degenerative
joint disorders such as osteoarthritis (OA). Altogether it is evident that sensory and sympathetic
neurotransmitters have crucial trophic effects which are critical for joint tissue and bone homeostasis.
They modulate articular cartilage, subchondral bone and synovial tissue properties in physiological
and pathophysiological conditions, in addition to their classical neurological features.
Keywords: osteoarthritis; neurotransmitters; peripheral nervous system; cartilage; subchondral bone;
CGRP; substance P; adrenoceptors
1. Introduction
Osteoarthritis (OA) is an age-related and/or trauma-induced multi-factorial, slowly progressing
and primarily non-inflammatory degenerative disorder of the synovial joints, culminating in the
irreversible destruction of the articular cartilage. Although OA is the most common musculoskeletal
condition that causes significant health and social problems worldwide, its exact etiology is still
unclear. Age-related wear, overuse, limb mal-alignment and genetic disorders, as well as metabolic
problems (obesity, immune responses, diabetes), play important roles in the onset of OA [1,2]. OA is
not exclusively a disorder of articular cartilage; it can be considered as an organ failure of the whole
joint with additional abnormalities especially in bone, ligaments, synovium and the joint capsule [3].
Clinical symptoms of OA appear in more than 10% of the world population and affect almost everyone
over the age of 65. As a consequence of the increasing longevity and obesity within the European
Community, the economic and social burden caused by OA is growing rapidly and substantially
influencing the life quality of affected individuals, with enormous costs to the health care system with
respect to diagnosis, treatment, sick leave, rehabilitation, and early retirement [4]. OA of the hips
and knees tends to cause the greatest burden to the population as pain and stiffness in these large
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weight-bearing joints often lead to significant disabilities requiring surgical intervention [5]. A recent
survey in 15 European countries revealed that on average 19% of the population suffers from chronic
pain, most frequently caused by disorders of the musculoskeletal system, specifically OA, herniated
and/or deteriorating discs, traumatic injury and rheumatoid arthritis [6].
Sympathetic and sensory nerve fibers innervate synovium, trabecular and subchondral bone,
bone marrow, periosteum and fracture callus [7,8]. Vascularization of the growth plate and matrix
differentiation during endochondral ossification in embryonic limb development are dependent
on the peripheral nervous system [9] which suggests a critical role in skeletal growth and limb
formation processes. Recently, our group demonstrated that femoral bone of substance P-deficient
and sympathectomized mice has inferior mechanical strength, reduced bone mass and trabecular
numbers [10].
Unlike other musculoskeletal connective tissues such as bone, periosteum and synovium, healthy
cartilage does not contain blood vessels and is not innervated by nerve fibers, indicating that cartilage
for some reason might be a hostile environment for spreading of nerve fibers. However, despite
lack of nervous innervation, cartilage metabolism is modulated and influenced by neurotransmitters
released either from nerve fibers located in neighboring tissue or directly from chondrocytes (for review
see [11,12]).
This review focusses on recent literature describing effects of sensory and sympathetic nerve
fibers and their neurotransmitters on joint tissue pathophysiology in OA affecting cartilage and
bone turnover.
2. Sensory and Sympathetic Nerve Fibers in Joint Physiology
Sometimes, sensory nerve fibers are observed in contact with a subpopulation of chondrocytes
located in growth cartilage and at the surface of articular cartilage [13,14]. Calcitonin gene-related
peptide (CGRP)-positive fibers, which originate from the periosteum and near insertion regions of
muscle and tendons, innervate up to 25 µm into the articular and meniscal cartilage tissues in rat
knee joints. These fibers are observed between individual chondrocytes, suggesting a local trophic
function different from their classical roles. However, subpopulations of substance P (SP)-positive
axons in perichondrium and periosteum have been detected which do not innervate the cartilage.
So far structural or molecular differences to those fibers which innervate cartilage have not yet been
described. CGRP- and SP-positive nerve fiber innervation precedes the development of cartilage
canals shortly after birth [15,16]. These fibers were detected inside the canals of growth cartilage in
the epiphysis of young rats, thus allowing physical contact to chondrocytes. Cartilage canals which
are invaded by sensory nerve fibers precede the development of the secondary ossification center.
Possibly, these nerve fibers modulate the formation of synovial joints by releasing trophic factors [17].
The authors observed that the inner layer of the perichondrium is richly innervated by peripheral
nervous fibers. These fibers were often found at the interface with the cartilage, in close contact with
the outer layers of epiphyseal chondrocytes which actively produce cartilaginous matrix and are
arranged in clonal grouping. These observations imply important functions of sensory nerve fibers for
regulating chondrogenic differentiation during limb growth in embryonic development.
Furthermore, bone and joint tissues like the synovium are densely innervated by sympathetic
nerve fibers. Tyrosine hydroxylase (TH)-positive catecholaminergic nerve fibers are mainly associated
with blood vessels but periosteal and bone-adjacent ligamental structures also contain free nerve
endings [18,19]. Nerve fibers showing immunoreactivity for the sympathetic neuropeptide vasoactive
intestinal peptide (VIP) were detected near epiphyseal trabecular bone, the periosteum and also in the
bone marrow compartment [20,21]. Work from Serre et al. identified an extensive network of neuronal
cell processes positive for the neuronal marker neurofilament 200 in the long bones of neonatal rats
which revealed tyrosine-hydroxylase (TH)- and VIP-immunoreactivity [22]. These nerve processes
coming in close contact with bone cells and medullary cells indicate a regulatory role for sympathetic
nerve fibers on bone cell activity during development. The importance of sympathetic innervation
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for bone homeostasis is undisputed but remains controversially discussed because stimulation and
inhibition of the sympathetic nervous system elicits anabolic as well as catabolic effects, being strictly
context-dependent [23–25].
3. Sensory and Sympathetic Nerve Fibers in Osteoarthritic Joints
3.1. Sensory Nerve Fibers and Neuropeptides
Suri et al. have localized both sensory (SP- and CGRP-positive) and sympathetic nerve fibers
(neuropeptide Y (NPY)-positive) in the articular cartilage in human tibiofemoral OA [26]. In addition,
they have detected blood vessels and nerves at the osteochondral junction and in osteophytes at the
human tibiofemoral joint. These nerve fibers were present within vascular channels in both mild and
severe OA-stages. It seems that in the pathogenesis of OA, fine unmyelinated nerves grow into joint
structures through vascular channels, mainly from subchondral bone breaching through the tidemark
rather than coming from synovium or periosteum.
The exclusively perivascular localization of nerves in the surface layer of articular cartilage implies
that vascularization is the driving force behind its innervation and without angiogenesis no nerve
fibers can grow into cartilage [26]. Free nerves, not associated with blood vessels, were not observed
within the articular cartilage. Vascularization of the non-calcified cartilage was found throughout
a wide range of histological OA stages and was not restricted to end-stage OA. Possibly, scoring of
nervous innervation and degree of vascularization of cartilage might be exploited as a measure for
severity of degradative changes in OA pathogenesis or even staging of disease progression. However,
the mechanisms that drive innervation of cartilage in OA have remained incompletely understood up
to now.
It is reported that in patients with knee OA, vascularization and accompanying innervation of
the articular cartilage might be a source of pain. Both sympathetic nerves and perivascular sensory
nerves innervate tibial osteophytes, with the sensory nerves detected at the base of osteophytes [26,27].
Radiological grading of osteophytosis is associated with reported pain severity in OA. The reason
may be the observed sensory innervation of osteophytes. Chronic pain sensation in OA is of profound
clinical importance but pain mechanisms are poorly understood. To date it has not been clarified
which joint tissues give rise to OA pain, and the nature of OA pain (nociceptive versus neuropathic) is
still debated [28]. One tissue compartment, which can be a source of pain in OA, is the osteochondral
junction. Interestingly, angiogenesis seems to predominate in both early and late OA, although, besides
proangiogenic factors, antiangiogenic factors are also upregulated in both OA stages as observed
in rats [29,30]. In OA, proangiogenic factors (such as vascular endothelial growth factor, VEGF) are
produced by chondrocytes [31] and the synovium [32,33] as well as in the subchondral bone, marrow
spaces and adjoining osteochondral channels. Chondrocytes in healthy joints produce antiangiogenic
factors, such as troponin I [34] and thrombospondin [35]. In OA, new blood vessels that cross the
tidemark in articular cartilage might be associated with sensory nerves, as might those in developing
osteophytes [26] and those that penetrate the inner regions of the meniscus [36]. Pain, the most common
problem of patients with arthritis (both rheumatoid arthritis (RA) and OA), is mediated by sensory
nerves. Perivascular nerve growth might contribute to pain in OA because nerve growth is associated
with peripheral sensitization, and nerves in structures such as cartilage that are not normally innervated
could be exposed to chemical stimulation and mechanical stress. Thus, neovascularization may
contribute to pain in patients with OA because of the accompanying sensory innervation. In addition,
innervation of other joint structures may contribute to OA pain. Ikeuchi et al. reported that in spite of
a significant decrease in total innervation in OA knees, the posterior cruciate ligaments (PCLs) have
constant nociceptive sensory innervation. In PCLs, constantly CGRP-immunoreactive nerve fibers in
both OA and non-OA knees, were detected, even though the PCLs in OA knees were statistically less
innervated than non-OA knees. Although the relationship between the decrease in total innervation in
PCLs and OA pathophysiology is still unclear, the PCL qualifies as the possible source of OA knee
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pain [37]. Clinical data from OA patients support an association between CGRP-immunoreactive
fibers in the joint and pain. Ashraf et al. demonstrated CGRP-positive sensory nerve profiles in the
outer region of menisci, and most of these nerves were associated with blood vessels [36]. Perivascular
CGRP-positive nerve fibers are increased in density in the menisci and joint capsules of patients
with high chondropathy scores and thus severe OA pathology. CGRP is co-localized with SP in
unmyelinated sensory nerve fibers, and therefore extends previous findings that perivascular nerves
containing SP were located in the peripheral portion of torn menisci. A study from Saxler et al. provides
the first immunohistochemical evidence that the innervation density of SP- and CGRP-immunoreactive
nerve fibers in the human hip joint is increased in patients with painful osteoarthritis. Patients with
painless hip failure completely lacked SP- and CGRP-positive fibers surrounding the joint [38,39].
During pathogenesis of OA, osteochondral angiogenesis is associated with increased nerve growth
factor (NGF) expression in subchondral spaces, vascular channels and in chondrocytes themselves [32].
Besides NGF synthesis, production of vascular endothelial growth factor (VEGF) and platelet-derived
growth factor (PDGF) were also associated with chondrocytes. VEGF-positive chondrocytes were
predominantly localized to the superficial zone of articular cartilage of OA samples and NGF-positive
chondrocytes were localized to superficial but not deep articular cartilage zones in OA. This NGF
immunoreactivity was co-localized with CGRP-immunoreactive nerve fibers in the same vascular
channels. Increased NGF production may thus contribute to OA pain, both structurally (increased
aberrant innervation at the osteochondral junction) and through peripheral sensitization. This was
confirmed in studies in human OA material, showing that increased vascular penetration and density
of perivascular CGRP—positive sensory nerve profiles in the meniscus are a potential source of pain
in knee OA and lead in addition to propagation of further inflammation and tissue damage [36,40].
It is unclear if sensory nerve fiber density during OA pathogenesis changes and whether the
sensory fiber profile is different from healthy joints. In a murine OA model (intraarticular injection
of collagenase), CGRP- and SP-positive nerve fibers disappeared 5 weeks after induction of OA [41].
In a similar OA model, Murakami et al. reported that the densities of protein gene product (PGP)
9.5- and CGRP-positive nerve fibers in the synovium were drastically decreased just one week
after the collagenase injection [42]. This aggressive and painful method of OA induction leads
to various degenerative alterations in synovial joint tissues (among other soft tissues) after a few
weeks. In contrast to these reports, some studies on human knee OA revealed an increase in SP- and
CGRP-positive nerve fiber density in the synovial tissue [38,39,43], whereas others have described
a decrease of these nerve fibers in the synovium [44]. As most of these studies are undertaken in
late-stage chronic OA, there is not much known about a potential association between the pathological
changes in knee tissues and changes in these nociceptive fibers innervation profile during the early
acute phase of the disease. It is likely that the normal vascular and neural network in early or late OA
stages is altered, however, the underlying molecular mechanisms have not yet been identified. In the
same line, it is unknown if nerves are destroyed as a consequence of OA or if pathogenesis of OA is
facilitated due to nerve disappearance (Figure 1).
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Figure 1. Proposed alteration of sensory and sympathetic nervous joint innervation in osteoarthritis. 
It is discussed that there is an increase of sensory nerve fiber innervation in the subchondral bone 
zone which reaches into the calcified cartilage zone from the subchondral bone or which comes into 
close contact to the articular cartilage. On the contrary, synovial sensory innervation decreases in an 
early osteoarthritis (OA) stage and presumably also in later OA stages. In addition, concentration of 
sensory neuropeptides in synovial fluid increases with increasing OA severity. In contrast, 
sympathetic innervation is presumably not profoundly changed during OA pathology. Modified 
from [12]. 
It was reported earlier that in a spontaneous age-related OA mouse model, loss of SP- and 
CGRP-positive innervation from the whole joint always preceded cartilage degeneration [45]. 
Immunocytochemistry showed that the percentage of neurons expressing SP and CGRP increased 
with age, whereas the spontaneous loss of general joint innervation and of the relative increase in 
peptide-expressing neurons occurred in the first year of life. Histological examination of knee joints 
of mice at various ages showed that loss of joint innervation always preceded histological changes of 
cartilage degeneration and surgical denervation accelerated cartilage degradation. The mice usually 
developed a mild form of osteoarthritis, but surgical ablation of joint innervation caused the 
development of severe patellofemoral OA. These findings would be consistent with the hypothesis 
that an age-related loss of sensory joint innervation may contribute to the development of OA. 
Whether sensory nerve fibers are lost, remain unaltered, increase or change tissue distribution as a 
prerequisite of OA pathogenesis in humans remains to be determined. Notably, CGRP and SP 
synovial fluid levels are increased in developmental dysplasia of the hip. CGRP concentration in 
synovial fluid is increased in knee OA patients and clearly correlated with increased 
Kellgren–Lawrence (KL) scores (indicating OA severity) [46–48]. Further insight into these 
mechanisms and relations requires reproducible OA-animal models resembling slow proceeding 
pathogenesis of human OA and enabling longitudinal studies from early onset of the disease to late 
stages. 
3.2. Sympathetic Nerve Fibers and Neurotransmitters  
Compared to sensory innervation, the influence of OA progression on sympathetic nerve fiber 
distribution and signaling or vice versa, is less well known and deserve more intense examination.  
In classical inflammation-driven diseases like RA, the local synovial innervation pattern is 
subjected to massive remodeling during disease progression. Synovial specimens from RA and OA 
patients undergoing knee joint replacement were compared for the expression of TH-positive and 
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It was reported earlier that in a spontaneous age-related OA mouse model, loss of SP- and
CGRP-positive innervation from the whole joint always preceded cartilage degeneration [45].
Immunocytochemistry showed that the percentage of neurons expressing SP and CGRP increased
with age, whereas the spontaneous loss of general joint innervation and of the relative increase
in peptide-expressing neurons occurred in the first year of life. Histological examination of knee
joints of mice at various ages showed that loss of joint innervation always preceded histological
changes of cartilage degeneration and surgical denervation accelerated cartilage degradation. The mice
usually developed a mild form of osteoarthritis, but surgical ablation of joint innervation caused the
development of severe patellofemoral OA. These findings would be consistent with the hypothesis that
an age-related loss of sensory joint innervation may contribute to the development of OA. Whether
sensory nerve fibers are lost, remain unaltered, increase or change tissue distribution as a prerequisite
of OA pathogenesis in humans remains to be determined. Notably, CGRP and SP synovial fluid levels
are increased in developmental dysplasia of the hip. CGRP concentration in synovial fluid is increased
in knee OA patients and clearly correlated with increased Kellgren–Lawrence (KL) scores (indicating
OA severity) [46–48]. Further insight into these mechanisms and relations requires reproducible
OA-animal models resembling slow proceeding pathogenesis of human OA and enabling longitudinal
studies from early onset of the disease to late stages.
3.2. Sympathetic Nerve Fibers Neurotransmitters
Compared to sensory innervation, the influence of OA progression on sympathetic nerve fiber
distribution and signaling or vice versa, is less well known and deserve more intense examination.
In classical inflammation-driven diseases like RA, the local synovial innervation pattern is
subjected to massive remodeling during disease progression. Synovial specimens from RA and
OA patients undergoing knee joint replacement ere compared for the expression of TH-positive and
SP-positive nerve fibers. In RA synovium a significantly lower number of TH-positive nerve fibers
and a significantly higher number of SP-positive nerve fibers were detected co pared to OA patients.
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Whereas the number of TH- and SP-positive nerve fibers was similar in OA patients, RA patients
showed a marked preponderance of sensory over sympathetic nerve fibers [49]. Both diseases are
associated with enhanced pain perception, but in OA-affected synovium the increase of sensory
innervation is quite reduced compared to RA. One possibility as to why OA progression is not
accompanied by pronounced changes in synovial innervation pattern might be that in RA, nerves play
a decisive role in perpetuation of the inflammatory response, whereas in OA inflammation does play
an important but less pointed role and the innervation profile might undergo more subtle changes
(Figure 1).
In an experimental rat model of temporomandibular joint OA, rats showed a robust sprouting
of TH-positive nerve fibers and increased norepinephrine (NE) levels in the condylar subchondral
bone compartment compared to control rats. This is in line with accelerated subchondral bone
loss, but so far no such observations have been reported for other OA joints [50]. The subchondral
bone of rat knee joints with monoiodacetate-induced OA showed clear sprouting of CGRP- and
tropomyosin receptor kinase A (TrkA)-immunoreactive fibers and this phenomenon was associated
with increased pain [51] (Figure 1). Interestingly, Ghilardi et al. demonstrated that in a mouse model
of chronic arthritic pain induced by Complete Freund Adjuvant (CFA) injection into the knee joint,
the sprouting of CGRP-positive sensory fibers in the synovium is accompanied by sprouting of
TH-positive sympathetic fibers in close proximity [52]. A more elaborated analysis of sympathetic
nerve fiber profile in different joint compartments in OA might therefore help understanding pain
behavior, but might also contribute to our knowledge about metabolic processes in OA with regard to
sympathetic neurotransmitter activity.
Due to the sparse availability of healthy human tissue for comparative analysis in
pathophysiological processes, Eitner et al. analyzed nerve fiber distribution in normal joints from rats
and sheep and compared their findings to human OA tissue samples [53]. They identified a dense
capillary network accompanied by a sympathetic and sensory neuronal network in normal synovial
tissue of rat and sheep joints. Non-inflamed tissue samples of OA patients showed a similar pattern
but according to the grade of inflammation of other tissue regions of these patients, the vascular
and neuronal network decreased and disappeared. Various degrees of local inflammation might
therefore evoke changes in innervation pattern of OA synovium comparable to RA and might also
induce TH expression in joint cells, providing a local source for NE as has been shown for synovial
macrophages [49]. In this line, our group demonstrated that chondrocytes of OA cartilage express TH
in all three cartilage zones with the weakest staining intensity in the deep zone [54]. With that, the cells
possess the prerequisite to induce an anti-inflammatory response in their immediate environment,
perhaps serving as a primarily protective measure in OA.
A recent review extensively elucidated the role of VIP in OA pathology [55]. The authors deduced
protective VIP characteristics in OA comparable with RA from the VIP content in OA synovial fluid
and articular cartilage which negatively correlated with progressive joint damage and disease severity.
The review also mentions one contradictory study which implicates VIP application in the OA knee
joint as a potential source of knee pain by sensitizing afferent nerves and enhancing the nerve fire
rate. In this particular study, intra-articular injection of VIP caused a rapid but transient algesic effect
evaluated by hind limb incapacitance measurements [56]. Furthermore, administration of the VIP
receptor antagonist VIP6–28 into the knee joint of rats with monoiodacetate-induced arthritis was
able to reduce this pain behavior, thereby showing for the first time that peripheral application of
VIP causes increased knee joint allodynia and secondary hyperalgesia. The anti-inflammatory and
anti-catabolic properties of VIP, which were demonstrated in arthritis before, might offer therapeutic
potential in OA, but the ability of VIP to promote hyperalgesia in OA joints needs to be more carefully
evaluated in order to consider VIP-targeted therapies in OA.
NPY-positive sympathetic nerve fibers were detected at the base of tibial osteophytes,
the subchondral bone marrow and within vascular channels of articular cartilage in OA. They were
similar in number to sensory nerve fibers in all compartments analyzed [26]. Differential NPY
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concentrations might represent a potential candidate as an OA biomarker due to known effects
on pain perception. In a study including 100 OA patients with varying grades of Watanabe pain
scores and radiographic stages, increasing synovial fluid concentrations of NPY correlated with
increasing pain scores [57]. NPY concentrations in OA patients were significantly higher compared
to controls and also middle and advanced stage OA patients exhibited higher NPY synovial fluid
concentrations compared to early-stage OA patients. NPY effects can therefore be associated with OA
pain but the synovial fluid levels do not correlate with radiographic OA stages. Additionally, to the
classical pain-associated neurotransmitters in OA, NPY might further contribute to pain but the exact
mechanisms need future examination.
4. Sensory and Sympathetic Neurotransmitters and Their Receptors in Chondrocytes
4.1. Sensory Neurotransmitters
Besides their classical function in nociception, SP and CGRP appear to have extra functions in
the musculoskeletal system. Previously, we described that newborn murine costal and adult human
articular chondrocytes endogenously produce SP and its neurokinin-1 receptor (NK1-R) [58]. Our data
suggest that also chondrocytes isolated from human OA and non-OA articular cartilage produce SP
and CGRP and carry receptors for both neuropeptides, the NK1-R and the calcitonin receptor-like
receptor (CRLR) (Figure 2). Expression of SP and its receptor was increased in chondrocytes and even
within the cartilaginous extracellular matrix after low-impact regimented exercise, indicating a role
in signaling pathways through which chondrocytes respond to mechanical stimulation. Blockade of
SP signaling by a chemical antagonist of the NK1-R inhibited chondrocyte responses to mechanical
stimulation (Figure 3). This was demonstrated by Millward-Sadler et al. who suggested that SP is
involved in mechanotransduction via the NK1-R [59,60]. In these experiments, SP was necessary to
elicit a hyperpolarization response of the cell membrane and, concomitant changes in gene expression
as response to mechanical stimulation indicate a role of SP in maintenance of articular cartilage matrix
integrity and function after mechanical stress. The same group demonstrated that normal and OA
chondrocytes reacted differently to mechanical stimulation in that OA chondrocytes upregulated gene
expression of the SP encoding gene, tachykinin (TAC) 1, whereas non-OA chondrocytes did not show
this phenomenon [61]. Notably, the transcription factor termed the neuron restrictive silencer factor
(NRSF) and the truncated splice variant, NRSF short form (sNRSF) which both are major modulators
of preprotachykinin A (TAC1) gene expression, were upregulated after mechanical stimulation in OA
chondrocytes only. This differential expression of TAC1 and sNRSF in OA chondrocytes suggests an
association of their expression with the disease. The change in expression of sNRSF and TAC1 mRNA
following mechanical stimulation in OA but not normal chondrocytes suggests that sNRSF may be
involved in the regulation of SP production in OA cartilage and might qualify as predictive marker for
diseased cartilage.
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and calcitonin gene-related peptide, CGRP (calcitonin receptor-like receptor, CRLR). Receptors for 
sympathetic neurotransmitters expressed in chondrocytes and bone marrow-derived macrophages 
(BMM)/osteoclasts were previously published [54,62]. SP = Substance P. 
In addition, we recently demonstrated that costal chondrocytes isolated from newborn mice 
increased their proliferative activity when stimulated with SP, which also increased cell-matrix 
adherence by inducing formation of focal adhesion contacts [58] (Figure 3). Our observation implies 
that SP might modulate proliferation rate of growth plate chondrocytes and consequently the 
terminal differentiation process during endochondral ossification, affecting longitudinal growth. 
Data from our group demonstrate expression of SP and NK1-R in the hypertrophic zone of growth 
plate chondrocytes [12]. It is thus conceivable that in chondrocyte physiology and in chondrogenic 
differentiation during skeletal growth, endogenous SP acts mainly as a trophic, anabolic factor and 
does not function as a classical neuropeptide.  
However, in adults, the detection of higher levels of SP in synovial fluid from patients with RA 
and OA, and increased expression of NK1-R, indicates possibly catabolic effects of SP on articular 
cartilage [63]. In other musculoskeletal diseases such as developmental dysplasia of the hip, 
increased levels of SP and αCGRP detected in synovium and synovial fluid indicate also catabolic 
and pro-inflammatory effects of these neuropeptides [47]. αCGRP concentrations in human serum 
and synovial fluid correlate with increasing KL grade and are lowest in controls without OA 
diagnosis [46]. In addition, transforming growth factor (TGF)-β and basic fibroblast growth factor 
(bFGF) play an important role as inductor or promoter for production of SP in synovial fibroblasts. 
These data are supported by Im et al. who elegantly demonstrated that SP induces interleukin 
(IL)-1β release [64] (Figure 3). The authors propose a mechanism by which bFGF, together with SP, 
reduce proteoglycan deposition and stimulates production and release of matrix metalloprotease 
(MMP)-13 in human articular chondrocytes and thus accelerates catabolic processes in cartilage.  
Figure 2. Receptors for sensory neuropeptides. On bone marrow-derived macrophages,
osteoclasts (white circles), and chondrocytes from OA cartilage (red fluorescence, detection by
Alexa568-coupled secondary antibody) as well as osteoblasts (green fluorescence, detection by
Alexa488-coupled secondary antibody) we detected receptors for SP (neurokinin 1 receptor, NK1-R)
and calcitonin gene-related peptide, CGRP (calcitonin receptor-like receptor, CRLR). Receptors for
sympathetic neurotransmitters expressed in chondrocytes and bone marrow-derived macrophages
(BMM)/osteoclasts were previously published [54,62]. SP = Substance P.
In addition, we recently demonstrated that costal chondrocytes isolated from newborn mice
increased their proliferative activity when stimulated with SP, which also increased cell-matrix
adherence by inducing formation of focal adhesion contacts [58] (Figure 3). Our observation implies
that SP might modulate proliferation rate of growth plate chondrocytes and consequently the
terminal differentiation process during endochondral ossification, affecting longitudinal growth.
Data from our group demonstrate expression of SP and NK1-R in the hypertrophic zone of growth
plate chondrocytes [12]. It is thus conceivable that in chondrocyte physiology and in chondrogenic
differentiation during skeletal growth, endogenous SP acts mainly as a trophic, anabolic factor and
does not function as a classical neuropeptide.
However, in adults, the detection of higher levels of SP in synovial fluid from patients with
RA and OA, and increased expression of NK1-R, indicates possibly catabolic effects of SP on
articular cartilage [63]. In other musculoskeletal diseases such as developmental dysplasia of the hip,
increased levels of SP and αCGRP detected in synovium and synovial fluid indicate also catabolic and
pro-inflammatory effects of these neuropeptides [47]. αCGRP concentrations in human serum and
synovial fluid correlate with increasing KL grade and are lowest in controls without OA diagnosis [46].
In addition, transforming growth factor (TGF)-β and basic fibroblast growth factor (bFGF) play an
important role as inductor or promoter for production of SP in synovial fibroblasts. These data are
supported by Im et al. who elegantly demonstrated that SP induces interleukin (IL)-1β release [64]
(Figure 3). The authors propose a mechanism by which bFGF, together with SP, reduce proteoglycan
deposition and stimulates production and release of matrix metalloprotease (MMP)-13 in human
articular chondrocytes and thus accelerates catabolic processes in cartilage.
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Figure 3. Effects of sensory and sympathetic neurotransmitters on chondrocytes. Changes in local 
innervation pattern of sensory and sympathetic nerves related to OA leading to altered neuropeptide 
microenvironments can alter chondrocyte behavior and metabolism contributing to the observed OA 
phenotype. (A) Substance P increases proliferation of chondrocytes indicating anabolic effects. 
Application of mechanical load increases expression of NK1-R and endogenous synthesis of 
substance P. Stimulation of synovial fibroblasts with SP induces release of inflammatory mediators, 
promoting cartilage degradation. (B) β2-AR signaling inhibits proliferation of chondrocytes whereas 
α1-AR signaling induces proliferation, implying dual effects of the sympathetic nervous system. NE 
signalling via α1-AR induces apoptosis of chondrocytes and signal transduction via β-AR inhibits 
chondrogenic differentiation of MSC and chondroprogenitor cells. GAG: Glycosaminoglycans; Col 
II: Collagen II; SP: Substance P; PGE2: Prostaglandine E2; MMP: Matrix metalloproteinase; IL: 
Interleukin; TNF: Tumor necrosis factor; NE: Norepinephrine; AR: Adrenoceptor; Iso: Isoproterenol; 
NK1-R: Neurokinin receptor 1; MSC: Mesenchymal stem cell. 
It is very likely that SP has autocrine functions and modulates physiological metabolism of 
chondrocytes and cartilage homeostasis during skeletal growth different from pathophysiology. In 
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Figure 3. Effects of sensory and sympathetic neurotransmitters on chondrocytes. Changes in local
innervation pattern of sensory and sympathetic nerves related to OA leading to altered neuropeptide
microenvironments can alter chondrocyte behavior and metabolism contributing to the observed
OA phenotype. (A) Substance P increases proliferation of chondrocytes indicating anabolic effects.
Application of mechanical load increases expression of NK1-R and endogenous synthesis of substance
P. Stimulation of synovial fibroblasts with SP induces release of inflammatory mediators, promoting
cartilage degradation. (B) β2-AR signaling inhibits proliferation of chondrocytes whereas α1-AR
signaling induces proliferation, implying dual effects of the sympathetic nervous system. NE signalling
via α1-AR induces apoptosis of chondrocytes and signal transduction via β-AR inhibits chondrogenic
differentiation of MSC and chondroprogenitor cells. GAG: Glycosaminoglycans; Col II: Collagen II;
SP: Substance P; PGE2: Prostaglandine E2; MMP: Matrix metalloproteinase; IL: Interleukin; TNF: Tumor
necrosis factor; NE: Norepinephrine; AR: Adrenoceptor; Iso: Isoproterenol; NK1-R: Neurokinin
receptor 1; MSC: Mesenchymal stem cell.
It is very likely that SP has autocrine functions and modulates physiological metabolism of
chondrocyt s and cartilage homeos asis duri g skeletal growth different fr m pathophys ology.
In synovial cells, SP is a potent diator of inflammation by promoting secretion of prostaglandin E2
(PGE2), several MMPs [65], reactive oxygen species [66], IL-1β and umor necr sis factor (TNF)-α [67].
Similarly, SP might induce catabolic pathways in chondrocytes promote cartilage degradation
(Figure 3).
To date, there are no reports listed in PubMed with respect to production of CGRP and its
recept r consisting of the two components CRLR/recep or activator modifying protein (RAMP) 1
in cartilage. However, we demonstrated expression of CRLR in articular cartilage chondrocytes
obtained from OA and non-OA patients mainly in middle and deep zones similar to the NK1-R [12].
In bo metabolism αCGRP is described as an a abolic factor which stimulates osteoblast activity
a d consequent y bone formation [21,68] (Figure 4). Possibly, αCGRP has similar anabolic effects in
cartilage physiology. Of note, inhibition of αCGPR effects by blocking its receptor with an antagonist,
attenuated subch ndral bo e scleros s in a murine surgical OA model (destabilization of the medial
meniscus) indicating a dual r le of CGRP in pathophysiology as eported for SP [69]. Conseque tly,
articular cartilage erosion and degener tion was delayed in the earl stage in this OA model but in a
later stag of the dise se these effect were abolished (8 week after OA induction). It is likely that
additional factors affect bone turnover and comp n ate for αCGRP effects.
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4.2. Sympathetic Neurotransmitters
Sympathetic nerve fibers and/or neurotransmitter-producing cells are present in different joint
tissues, except in articular cartilage and the avascular zone of the meniscus [49,70]. These data
indicate that neurotransmitters released into the synovial fluid can influence cartilage tissue and
chondrocyte metabolic activity provided that specific adrenergic neurotransmitter receptors are present
on chondrocytes.
In neonatal mouse tibial sections, β2-adrenoreceptor (AR) and α2A-AR mRNA expression was
detected in chondrocytes by in situ hybridization [71]. All other adrenergic receptors were not present.
Similarly, our group described that β2-AR and α2A-AR mRNA but also α1B-AR and α1D-AR were
expressed in newborn murine costal chondrocyte cultures [58]. An earlier study performed by Lai et al.
confirmed only the expression of β2-AR on growth plate chondrocytes from ribs of embryonic E18.5
mice [72]. Studies on cartilage tissue explants isolated from OA patients after endoprothetic surgery
and on chondrogenic progenitor cells obtained from human OA cartilage explants revealed that
also under degenerative conditions, β2-AR and α2-AR are present [54,70]. As it is suggested that
many biomechanical pathways in OA pathogenesis are altered, it is conceivable that β2-AR might
contribute to disease development related to overloading of cartilage, because β2-adrenergic drugs
have been shown to influence mechanical events in bone tissue [21,73]. Cumulative genetic evidence
strongly supports the biological relevance of β2-AR signaling in the regulation of bone remodeling [73]
(Figure 4). The observation that osteoblast-specific inactivation of the β2-AR induces a high bone mass
phenotype confirmed the osteoblast-specific role of the β2-AR in the regulation of bone remodeling
and supported the notion that sympathetic signals, mainly via the β2-AR expressed in osteoblasts,
restrain bone formation and favor bone resorption [74].
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Peptidergic NPY receptors play an important role in bone homeostasis [75,76] but no data exists
about chondrocytes expressing NPY receptors. Only one study so far has confirmed the existence of
the Y1 receptor on bone marrow stromal cells being able to contribute to cartilage repair processes [75].
Similarly, no studies have described the presence of VIP receptors on chondrocytes until now.
Sympathetic neurotransmitters control chondrogenic progenitor cell differentiation and mature
chondrocyte function but up to now adrenoreceptor expression levels were not compared between
healthy and pathological conditions. Bone marrow-derived stem cell (BMSC) migration from the bone
marrow towards adjacent tissues is affected by catecholamines either released by sympathetic neurons
or by immune cells. Besides sympathetic nerves located in the bone marrow, resident bone marrow
cells also synthesize substantial amounts of catecholamines [77,78]. Thus, increased sympathetic
neurotransmiiter concentrations during stress or in an inflammatory situation might critically influence
progenitor cell physiology in the bone marrow. Moreover, NE (and dopamine) release is subject to a
circadian rhythm with early morning peaks. Furthermore, treatment of murine pre-chondrogenic cells
with epinephrine resulted in β2-AR-dependent inhibition of Sox9 gene expression and consequently of
chondrogenic gene expression via classical Gαs-cyclic adenosin mono phosphate (cAMP) signaling [71]
(Figure 3). Similarly, NE inhibited chondrogenic differentiation of BMSC and OA-cartilage-derived
progenitor cells [70]. Via β2-AR-signaling, NE in high concentrations repressed collagen II and
glycosaminoglycan deposition (Figure 3) and accelerated the expression of hypertrophic markers like
collagen X and MMP-13. NE in low concentrations, acting preferentially via α-AR, had no effects.
In contrast to findings in progenitor cell chondrogenesis studies, Lai et al. reported that the
specific β2-AR agonist isoproterenol inhibited indian hedgehog (IHH) and collagen X expression via
cAMP and extracellular signal-regulated kinases (ERK)-1/2 activation in the murine growth plate [72].
Furthermore, isoproterenol stimulated the proliferation of chondrocytes (Figure 3). In a follow-up
study, these authors elaborated on the involvement of the transcription factor Jun-B, activated by β2-AR
in chondrogenesis, inhibiting the expression of Sox6 and collagen II [79] similarly to mesenchymal
stem cells (MSCs) [70]. In costal chondrocytes isolated from newborn mice, apoptosis decreased after
NE stimulation, however, extracellular matrix formation with respect to collagen and proteoglycan
production was not influenced by NE in that experimental setup [58] (Figure 3).
NE modulates the function of human OA chondrocytes. In OA, inflammation and activation of
the innate immune system is recognized as an important hallmark. However, not so much is known
about the effect of inflammation on chondrocyte function in OA. For instance, Lorenz and colleagues
investigated the effects of NE together with an inflammatory stimulus like IL-1β, simulating an
early OA microenvironment [54]. NE in high concentrations decreased chondrocyte proliferation via
β2-AR signaling. In contrast, NE in low concentration increased the proliferation of OA chondrocytes
via β1-AR signaling, suggesting that NE might exhibit dual effects on chondrocyte proliferation
in OA depending on sympathetic activity (Figure 3). In addition, NE reversed IL-1β-mediated
suppression of collagen II and glycosaminoglycan synthesis at high concentrations. Furthermore,
our group showed for the first time that some chondrocytes which are present in OA cartilage are
TH - positive. This indicates that the presence of sympathetic nerve fibers (in contrast to RA) and a
high sympathetic activity might be beneficial in OA. However, no in vivo evidence exists at present
confirming this hypothesis.
Taken together, all those reports discussed above are providing different and partly controversial
data which do not allow a clear prognosis in which way sympathetic neurotransmitters contribute to
chondrogenesis of progenitor cells and in mature chondrocytes to articular cartilage repair in both a
non-inflammatory and an inflammatory microenvironment.
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5. Sensory and Sympathetic Neurotransmitters and Their Receptors in Subchondral Bone
5.1. Sensory Neurotransmitters
Disturbed skeletal homeostasis has been observed in patients suffering from stroke, spinal cord
injuries and other nerve injuries [80,81]. Degradative biomarkers from serum of these patients implied
an uncoupling of the bone remodeling process in favor of bone resorption. The effect was mainly
attributed to an unloading of the affected limbs but animal studies in rats using guanethidine-induced
reduction in VIP and NPY levels showed induced osteoclastogenesis in the mandible without affecting
periosteal bone formation [82]. Furthermore, surgical and chemical sympathectomy in Mongolian
gerbils led to enhanced osteoclast resorptive activity in ear bones which are not normally subjected
to loading [83]. Clearly, mechanisms not directly related to loading are responsible for skeletal
changes following denervation. Numerous studies demonstrated the expression of receptors for a
wide variety of neurotransmitters and neuropeptides on bone cells like osteoblasts and osteoclasts
and tried to elucidate the influence on their cellular activities. To date, there are major limitations
regarding our understanding of the influence of changes in innervation pattern of subchondral bone
on the remodeling processes of bone observed in OA. So far, observations from studies of neuronal
influence on bone cells can serve as references but gaining a clearer insight into actual pathological
neuronal–skeletal interactions in OA will require considerable research efforts in the future.
5.1.1. Substance P Effects on Osteoblasts
The extensive distribution of SP in joint tissues and also bone has been described earlier, including
NK1-R, which is widely expressed in bone cells as osteoblasts, osteoclasts and osteocytes indicating
a modulatory capacity of SP in bone remodeling. Goto et al. detected NK1-R expression in the
cytoplasm and the plasma membrane of rat osteoclasts [84]. Compared to osteoclasts, in osteoblasts
and osteocytes weaker immunoreactivity for the NK1-R was observed. However, missing additional
studies evaluating the function of the receptor in these cell types makes it difficult to draw conclusions
from the differential distribution of the NK1-R between osteoblasts and osteoclasts. In a very early
study by Bjurholm et al., SP (and NPY) was not able to induce a cAMP response in rat osteosarcoma
cell lines UMR-101-01 and ROS 17/2.8, the human osteosarcoma cell line Saos-2, a mouse calvarial
pre-osteoblastic cell line, MC3T3-E1, and in primary mouse neonatal calvarial bone cells, indicating a
minor role for SP in osteoblast function regulation [85]. However, work from Azuma et al. instead
showed that SP enhanced the Porphyromonas gingivalis lipopolysaccharide-induced inhibition of
bone nodule formation and alkaline phosphatase (ALP) activity in rat calvarial osteoblasts [86].
In contrast, various studies addressing SP effects on osteoblastic cells reversed these findings. Goto et al.
reported an upregulation of the NK1-R in primary rat calvarial osteoblastic cells after 14 days of
osteogenic differentiation, but not after 7 days, that promoted bone formation upon addition of SP
to the culture medium [87]. In late-stage osteogenesis, addition of SP to the cell culture medium
also stimulated osteocalcin, runt-related transcription factor (Runx) 2 and collagen I expression,
but not in the early differentiation stage. From that observation the authors concluded an influence
of SP on more mature osteoblast cells rather than on pre-osteoblastic cells, explaining some of
the controversial findings indicated above as some of the cell lines investigated in the study by
Bjurholm et al. represent rather early osteoblastic stages. Meanwhile, a number of investigations
showed that SP promotes upregulation of the osteogenic transcription factor osterix during osteogenic
differentiation of mesenchymal stem cells [88], activates the pro-osteoblastic Wnt-signaling pathway
in MC3T3-E1 cells [89] and stimulates human osteoblastic cell activity by enhancing gap junction
intercellular communication [90].
In a very recent study, Kodama et al. describe a bi-directional communication of osteoblastic
MC3T3-E1 cells and dorsal root ganglion-derived sensory neurons [91]. The authors show that the
efferent signal is transmitted via SP and glutamate and that osteoblast-like cells communicate to the
afferent neural arm via adenosine triphosphate (ATP) exocytosis after perception of an inflammatory
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stimulus like bradykinin. From these observations, the authors hypothesize that osteoblasts and
possibly other bone surface cells might serve as sensors for environmental stimuli and transmit
this perception to the central nervous system via afferent nerves. These novel observations might
broaden our knowledge and add even more complexity to the regulatory circuits involved in bone
homeostasis, and have to be taken into consideration when evaluating studies targeting neuronal
effects in the skeleton.
5.1.2. Substance P Effects on Osteoclasts
While SP effects differ in early and mature osteoblasts, there is a consensus that SP stimulates
osteoclastogenesis and favors bone resorption either directly [92,93] or indirectly by upregulation
of the major osteoclast differentiation factor receptor activator of the nuclear factor (NF)-κB ligand
(Rankl) in various cell types [94,95]. Contrary to the physiological situation, information on the effects
of SP in bone in osteoarthritic conditions is sparse. Xiao et al. showed an increase in mean optical
density for SP immunoreactivity (and also CGRP and VIP) in the cancellous bone of OA femoral heads
compared to osteoporosis samples, which correlated positively with pain intensity analyzed by visual
analog scale (VAS) but also with bone structural parameters analyzed by micro computer tomography
(µCT) [96]. Concluding from this, SP might be implicated in OA pain but also seems to rather preserve
bone structure in OA pathophysiology. Zhen and co-workers elegantly demonstrated that anterior
cruciate ligament transection leads to spatiotemporal uncoupling of bone remodeling with an increase
of osteoblast and osteoclast activity in an OA mouse model [97]. How local release of SP in bone
tissue might be involved needs to be further elucidated, but acting as enhancer on both cell types,
SP could contribute to these observations and SP targeted therapies could potentially target OA bone
phenotypes too.
5.1.3. CGRP Effects on Osteoblasts and Osteoclasts
Expression of the main CGRP receptor complex composed of CRLR and receptor activity
modifying protein (RAMP) 1 (its co-receptor) has been demonstrated on several osteoblastic cell
lines like MC3T3-E1 and MG63, rat primary calvarial osteoblasts and human primary osteoblast
cultures [68,98–100]. Addition of CGRP to bone marrow stromal cells, subjected to osteogenic
differentiation, enhanced proliferation and expression of osteoblastic genes like Runx2, ALP, osteocalcin
and col1a1 [101]. CGRP stimulation dose-dependently induced cAMP production and affected
intracellular Ca2+-level in primary osteoblastic cells isolated from calvaria of newborn rabbits [102].
In addition, it induced the expression of osteoblastogenic activating transcription factor-4 (ATF-4) and
osteoprotegerin (OPG) while decreasing expression of Rankl. Increasing the OPG/Rankl ratio and
thus favoring osteoblast differentiation would shift the skeletal balance towards bone formation and
emphasizes the anabolic character of CGRP. The indirect inhibitory effect of CGRP on bone resorption
was additionally confirmed in the MC3T3-E1 pre-osteoblastic cell line where it downregulated Rankl
and upregulated OPG, independently of mechanical stimulation [103]. Supporting the preserving
effect of CGRP on bone matrix, different studies reported an inhibitory influence of CGRP on
osteoclastogenesis. CGRP inhibited IL-1 induced osteoclastic bone resorption in a co-culture setup
with osteoblasts on ivory slices either directly or indirectly [104]. In fetal rat osteoblasts, CGRP was
able to inhibit the lipopolysaccharide (LPS) and IL-1-induced production of TNF and weakly induced
IL-6 in these osteoblasts [105]. These inhibitory effects seemed to be not only mediated by classical
cAMP-dependent pathways, but also the protein kinase C pathway. The indirect inhibitory effect of
CGRP on osteoclastogenesis was demonstrated by regulating the Rankl/OPG ratio in osteoblast-like
cells. Besides osteoblasts, osteoclasts and their precursors, bone marrow-derived macrophages (BMM),
also express the CGRP receptor complex of CRLR and RAMP1 [106]. In addition, RAMP2 and 3 mRNA
and protein expression was detected in osteoclasts, which points to regulatory control from other
proteins of the calcitonin family apart from CGRP, i.e., amylin, adrenomedullin and intermedin.
Wang et al. reported that CRLR immunostaining was more intense in BMMs and pre-osteoclasts
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compared to mature osteoclasts [101]. When they subjected BMMs to macrophage colony-stimulating
factor (M-CSF)/Rankl induced osteoclast differentiation under CGRP stimulation, the cell cultures
yielded reduced osteoclast numbers, erosion areas on osteologic discs were smaller and the mRNA
expression of tartrate-resistent alkaline phosphatase (TRAP) and cathepsin K, two marker genes for
mature osteoclasts, was reduced.
With regard to a complex disease like OA, every patient has some variation in subchondral
bone and neuronal phenotype and, in many other aspects, variations in distribution of SP- and
CGRP-positive nerves or synovial fluid/serum concentrations of these neuropeptides might correlate
with individual subchondral bone radiographic status due to their partly opposite effects on bone cells.
5.2. Sympathetic Neurotransmitters
A similar complexity for neuronal regulation of bone cell function and differentiation is observed
for neurotransmitters of the sympathetic nervous system like VIP, NPY and NE. In particular,
NE potentially exerts a wide range of effector functions because of the multitude of receptors used
by this neurotransmitter. Functional expression of the adrenoceptors α1B and β2 was detected by
reverse transcription polymerase chain reaction (RT-PCR) and immunofluorescence staining in human
osteoblast cells by Huang et al. [107]. Earlier studies were able to prove α- and β-AR expression
mainly on gene expression level [98]. Protein levels of the α-receptors were low, consequently an
influence of α-adrenergic regulation of bone cells remained questionable. An in vitro study using
intertrochanteric trabecular bone samples from osteoporotic- and OA patients also detected theα2A-AR
via immunostaining in cuboidal shaped osteoblasts and bone lining cells but not on osteocytes [108].
Pharmacological targeting of α-AR elucidated the role of these receptors in osteoblast-like cells.
Usage of the α-AR agonists cirazoline and phenylephrine and the β-AR-blocker propranolol induced
the proliferation of human osteoblasts whereas fenoterol, a β2-AR-agonist, inhibited osteoblast
proliferation. Both agonists also dose-dependently enhanced the expression of Rankl and OPG,
thus indicating an indirect regulatory influence on osteoclasts [107] (Figure 4). In the human osteoblast
SaM-1 cell line, NE was able to induce cell proliferation via blockade of a potassium channel using a
Gi/o signaling pathway. The effect was blocked by chloroethylclonidine, an α1B-AR antagonist [109].
The pro-osteoblastic effect of α-AR agonism was also observed by Tanaka and co-workers [110].
They reported that phenylephrine, a non-specific α1-AR agonist, induced the transcription factor
CCAAT/enhancer-binding protein δ (CEBPD) in the pre-osteoblastic cell line MC3T3-E1 enhancing the
proliferation of these cells. These studies indicate that noradrenergic signaling via α-ARs is primarily
a positive regulator of osteoblast differentiation and an indirect inhibitor of osteoclasts.
Primary neonatal mouse calvarial osteoblasts from fluorescent ubiquitination-based cell cycle
indicator (FUCCI) transgenic mice, expressing red nuclear fluorescence markers in osteoblasts in the G1
phase of the cell cycle and green fluorescence markers in the G2/M phase, were analyzed for the effects
of the β-AR-agonist isoproterenol on osteoblast proliferation and migration. The isolated osteoblasts
were capable of bone nodule formation in osteogenic medium, stating that the genetic engineering
did not affect normal bone formation behavior. Isoproterenol suppressed migration velocity and
distance and delayed cell cycle transition and thus proliferation, indicating that these effects add
to disuse-induced bone loss [111]. Disuse-induced bone loss is a major side effect in age-related
diseases leading to osteoporosis. The sympathetic tone has been discovered as a major origin of the
disease-inducing signal [24]. When MC3T3-E1 cells were treated with the β-AR-agonist isoproterenol,
adrenoceptor signaling significantly suppressed a bone morphogenetic protein (BMP)-2 induced
increase in ALP expression in these cells [112]. Additionally, β-adrenergic stimulation led to enhanced
Rankl expression in the osteocytic cell line MLO-Y4 which in turn induced osteoclastogenesis in
osteocyte–RAW264.7 co-cultures [113]. Opposite effects of noradrenergic α- and β-AR signaling have
been reported eliciting pro- and anti-inflammatory effects for RA and likewise changes in sympathetic
innervation pattern in OA would provide an altered local neurotransmitter milieu. Thus, bone cell
regulation could change and/or induce aberrant remodeling of subchondral bone.
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Work from our group detected the protein expression of adrenoceptorsα1D,α2B andβ2 on mature
osteoclasts as well as on rat BMM, the osteoclastic precursor population [62,114]. We have shown that
α-adrenergic stimulation with 10−8 M NE increased osteoclast differentiation whereas β-adrenergic
stimulation with 10−6 M instead decreased osteoclastogenesis (Figure 4). Furthermore, NE increased
caspase 3/7-mediated apoptosis in the mixed cultures of BMM and osteoclasts. When rat BMMs were
removed from a highly inflammatory environment, like in inflammatory arthritis, and subjected to
M-CSF/Rankl-driven osteoclastogenesis, their reactivity to NE was altered with regard to osteoclast
numbers, apoptosis and especially cathepsin K activity [62]. Although in OA inflammation is less
prominent compared to RA, inflammatory mediators in joint adjacent bone compartments might
influence neurotransmitter reactivity of local osteoclasts, thereby promoting alterations in bone
metabolism. In contrast to our study and in support of earlier studies, Aitken et al. showed that β2-AR
stimulation enhanced osteoclastogenesis indirectly as well as directly [115,116]. Work by Kondo et al.
demonstrated that the osteoclastogenic effect of β2-AR stimulation was at least partly mediated by
induction of reactive oxygen species [117]. These conflicting observations might be due to different
stimulation regimen which addressed early and late stage differentiation of osteoclasts comparable to
the aforementioned differential effects of SP on early and late stage osteoblastogenesis.
Information on changes of bone innervation during OA pathogenesis is rare. Studies using OA as
comparative controls for respective analysis in RA patients where sympathetic nerve fibers get lost,
show that presumably sympathetic innervation is less affected by OA-induced changes than sensory
innervation. Inflammatory mediators are also evident in OA, although to a lesser extent than in RA.
As we have shown in our work, inflammatory conditions might change the reactivity of osteoclast
precursors thereby evoking an altered bone metabolism [62,114]. Thus, one might hypothesize that
not necessarily innervation patterns change but the reactivity of cells by either modulating receptor
expression or alteration of intracellular signal transduction.
Receptors for the neuropeptide VIP and its related moleculepituitary adenylate cyclase activating
peptide (PACAP), mainly associated with anti-inflammatory reactions, were also detected on
osteoclasts and osteoblasts of different species like human, mouse and rat as reviewed by [118].
In osteoblasts, VIP application elicited a cAMP response and led to induction of ALP gene expression
and activity (Figure 4), stimulated IL-6 expression and increased the stimulatory effect of a number of
cytokines on IL-6 production. In a co-culture system, VIP caused a delayed enhancement of osteoclast
resorptive activity but in M-CSF/Rankl-induced osteoclastogenic cultures of BMM, VIP inhibited
osteoclast formation. From that observation, the authors concluded that VIP regulates the expression
of osteoclastogenic factors in osteoblasts [119]. A recent review by Juhasz et al. further highlighted the
role of VIP in osteogenic signaling pathways [120]. VIP upregulates the transforming growth factor
(TGF) β/BMP signaling pathway and the pathway’s effector molecules, SMADS, can in turn regulate
VIP expression, leading to more complex reciprocal regulatory mechanisms. VIP is also implicated
in direct activation of the ERK1/2 pathway in osteoblasts, thereby enhancing the Rankl/OPG ratio.
From this activation of the ERK signaling pathway the authors deduced that VIP might also promote
osteoblastogenesis like it was shown for activation of the fibroblast growth factor receptor 2. However,
the authors provided no direct evidence for comparable VIP effects. Our group detected mRNA
expression of VIP receptor 1 and 2 and the alternative VIP receptor PACAP receptor 1 in mixed
cultures of osteoclasts and BMMs [62]. We observed that VIP had no profound effect on osteoclast
numbers, but VIP-treated cultures showed a significantly reduced cathepsin K activity in the cell
culture supernatant (Figure 4). VIP actions indicate an anabolic function in the skeletal system
and protective effects of VIP application preventing destruction of bone and cartilage have been
demonstrated in collagen-induced murine arthritis [121]. Therefore, VIP appears as a very attractive
therapeutic option in OA.
The osteoblastic actions of NPY were recently very extensively reviewed by [122]. NPY actions on
bone are not only derived from central neuronal signals but also from a highly complex peripheral
network. Peripheral and thus bone resident NPY can be released from sources like sympathetic
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nerves, the adrenal medulla, pancreatic tissue or osteoblasts and osteocytes themselves, which produce
NPY endogenously. The local production of NPY is involved in regulation of bone homeostasis by
suppressing bone formation and modulating osteoblast progenitor commitment via the Y1 receptor.
Most of the work in this review describes results from mouse experiments. In isolated human MSC
under osteogenic conditions, NPY directly promoted osteogenesis by up-regulation of Runx2 and
an increase in ALP-activity and Alizarin red staining (Figure 4). In contrast to mouse studies, the Y1
receptor mRNA was upregulated in the course of osteogenic differentiation of human MSC [123].
There might be a discrepancy in NPY receptor response in various species that needs consideration
when evaluating new treatment targets in whole joint diseases like OA. Studies on NPY and osteoclasts
are rare and so far, only one study describes that BMM cultures from mice lacking expression of the
NPY receptor y6R showed an increase in M-CSF/Rankl induced osteoclastogenesis [124], indicating
that NPY actions are preservative in the bone environment.
6. Perspectives
Sensory and sympathetic nerve fibers and their neurotransmitters are important neuronal
effectors regulating cartilage and bone physiology and playing decisive roles in musculoskeletal
pathophysiologies. Notably, many resident cells of the osteoarticular system have receptors for
sympathetic and sensory neurotransmitters, thus, they can respond to these stimuli. Embryonic limb
growth and post-natal long bone growth is modulated via sympathetic and sensory neurotransmitters
by targeting chondrocytes in the growth plate. It becomes more and more evident that neuronal
signaling critically influences tissue regeneration, i.e after bone and meniscal traumata and
tendon/ligament ruptures. However, it is not well understood and discussed controversially
in literature how changes in sensory and sympathetic nerve fiber profile and their respective
neurotransmitters contribute to abnormal subchondral bone remodeling, cartilage degradation and
osteophyte formation during the pathogenesis of OA.
Taken together, it becomes more and more evident that sensory and sympathetic nerve fibers
and their neurotransmitters critically influence cartilage, subchondral bone, and other joint tissue
function and homeostasis. Without doubt, the peripheral nervous system is crucially involved in
the pathogenesis of musculoskeletal disorders such as OA and others and cannot be ignored in the
analysis of underlying molecular mechanisms.
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